ENDO: Oxytocin Shows Promise in Overweight/Obese Men

This article originally appeared here.
Share this content:
ENDO: Oxytocin Shows Promise in Overweight/Obese Men
ENDO: Oxytocin Shows Promise in Overweight/Obese Men

MONDAY, April 4, 2016 (HealthDay News) -- Overweight/obese men receiving a dose of oxytocin nasal spray act less impulsively and exert more control over their behavior compared with men receiving placebo, according to a study presented at the annual meeting of The Endocrine Society, held from April 1 to 4 in Boston.

Franziska Plessow, Ph.D., from Massachusetts General Hospital/Harvard Medical School in Boston, and colleagues performed a double-blind, placebo-controlled crossover pilot study involving 10 healthy overweight/obese men. Participants completed a stop-signal paradigm 15 minutes after receiving a nasal dose of oxytocin or placebo. The paradigm assesses strategy and ability to suppress behavioral impulses. Participants categorize stimuli by pressing response keys, and when a stop signal appears are instructed to withhold their response.

The researchers found that subjects showed increased reaction times in the go task after receiving oxytocin versus placebo (P = 0.012). Under oxytocin versus placebo, fewer stop errors were displayed by the participants (P = 0.049).

"Our preliminary results in men are promising," Plessow said in a statement. "Oxytocin nasal spray showed no strong side effects and is not as invasive as obesity surgery."

Abstract
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »